Live Evaluations

New Developments in Psoriasis: Clinical Insights for Dermatology Providers

About

New Developments in Psoriasis: Clinical Insights for Dermatology Providers.

This activity is supported by an educational grant from Arcutis Biotherapeutics, Inc.

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Identify challenges associated with the use of topical corticosteroids in patients with psoriasis

  • Review nonsteroid topical agents for the treatment of psoriasis

  • Discuss clinical considerations for dermatologists who prescribe nonsteroidal topical therapies to patients with psoriasis

Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
Alexandra
Alexandra Golant, MD

Medical Director, Dermatology Faculty Practice
Associate Director, Residency Program
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

Mark
Mark Lebwohl, MD

Dean for Clinical Therapeutics
Waldman Professor
Chairman Emeritus
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada and CMEsquared. The University of Nevada is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Nevada designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers

CONFLICTS OF INTEREST/DISCLOSURES

In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer. 

Disclosures are as follows:

Alexandra Golant, MD

Consultant: Regeneron, Sanofi, Lilly, Incyte, Dermavant, Arcutis, LEO Pharma, Janssen 

Speakers’ Bureau or Honoraria: Regeneron, Sanofi, Lilly, Incyte, Dermavant, Arcutis 

Mark Lebwohl, MD

Grant/Research Support: Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara Therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Novartis, Ortho Dermatologics, Regeneron, and UCB, Inc.

Consultant: AnaptysBio, Arcutis, Inc., Arena Pharmaceuticals, Aristea Therapeutics, Avotres Therapeutics, BioMX, Boehringer-Ingelheim, Brickell Biotech, Cara Therapeutics, Castle Biosciences, Corevitas, Dermavant Sciences, Evommune, Inc., Facilitation of International Dermatology Education, Hexima Ltd., Meiji Seika Pharma, Mindera, National Society of Cutaneous Medicine, New York College of Podiatric Medicine, Pfizer, Seanergy, SUN Pharma, Verrica, and Vial.

The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.  

The University of Nevada discloses that all relevant conflicts have been satisfactorily mitigated.


Dermsquared

The leading platform for dermatology professionals to elevate patient care.

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2023 dermsquared | All Rights Reserved